
Elranatamab reduced the risk of disease progression or death vs standard care in patients with R/R myeloma after prior anti-CD38 therapy and lenalidomide.
Dr. Bose discusses his perspective on quality-of-life preservation for his patients with myelofibrosis, including the symptoms that have the most negative impact on patients' quality of life.
Case:Â Intermediate-Risk Primary Myelofibrosis in a 68-Year-Old Woman
Clinical Presentation:
PM: No known comorbidities
Initial Clinical Workup and Diagnosis:
Initial Treatments:
